Maximum Tolerated Dose of Lenalidomide Beginning from 1st Dose Until Not Tolerated - Phase I [clinicaltrials_resource:4a3b2fa3efe686562ba111c0d93b1c03]
Phase I of study: Lenalidomide at cohort specific assigned dose and schedule (starting at 10 mg by mouth per day on days 1-28) of a 28 day cycle with 40 mg/m^2 of liposomal doxorubicin given intravenously (IV) on day 1 of a 28 day cycle.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Maximum Tolerated Dose of Lenalidomide Beginning from 1st Dose Until Not Tolerated - Phase I [clinicaltrials_resource:4a3b2fa3efe686562ba111c0d93b1c03]
Phase I of study: Lenalidomide at cohort specific assigned dose and schedule (starting at 10 mg by mouth per day on days 1-28) of a 28 day cycle with 40 mg/m^2 of liposomal doxorubicin given intravenously (IV) on day 1 of a 28 day cycle.
Bio2RDF identifier
4a3b2fa3efe686562ba111c0d93b1c03
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:4a3b2fa3efe686562ba111c0d93b1c03
measure [clinicaltrials_vocabulary:measure]
Maximum Tolerated Dose of Lenalidomide
time frame [clinicaltrials_vocabulary:time-frame]
Beginning from 1st Dose Until Not Tolerated - Phase I
description
Phase I of study: Lenalidomide ...... V) on day 1 of a 28 day cycle.
identifier
clinicaltrials_resource:4a3b2fa3efe686562ba111c0d93b1c03
title
Maximum Tolerated Dose of Lena ...... Until Not Tolerated - Phase I
@en
type
label
Maximum Tolerated Dose of Lena ...... b2fa3efe686562ba111c0d93b1c03]
@en